Danish multinational pharmaceutical company Novo Nordisk has announced plans to invest DKK 850 million in expanding its production facilities in Kalundborg, Denmark.

This new investment brings Novo Nordisk’s total investments in site Kalundborg to more than DKK 2 billion in 2020.

Novo Nordisk currently manufactures a range of diabetes care products in Kalundborg, and the new investment will be used to rebuild and expand an existing production facility to create additional capacity for manufacturing the pharmaceuticals of the future.

In February, Novo Nordisk announced an investment of DKK 800 million in upgrading and expanding facilities at its production site in Kalundborg to ensure capacity for future production of existing and new-generation diabetes care products.

In May, the company announced a further investment of DKK 150 million in a new tablet packaging production line, followed up in June by an investment of DKK 225 million.

The new investment of DKK 850 million will expand the company’s capacity for manufacturing the products of the future.